Section Arrow
Quote
AARD.NASDAQ
- Aardvark Therapeutics Inc
Quotes are at least 15-min delayed:2025/11/03 23:25 EST
Regular Hours
Last
 10.39
-0.3 (-2.81%)
Day High 
10.7362 
Prev. Close
10.69 
1-M High
17.94 
Volume 
240.48K 
Bid
10.5
Ask
10.4
Day Low
9.9 
Open
10.66 
1-M Low
10.2264 
Market Cap 
231.90M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 11.31 
20-SMA 13.35 
50-SMA 11.66 
52-W High 19.58 
52-W Low 4.88 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.69/-2.83
Enterprise Value
232.34M
Balance Sheet
Book Value Per Share
6.31
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
PHIOPhio Pharmaceuticals Corp1.86-0.19-9.27%0.01PE
CRBUCaribou Biosciences2.43+0.01+0.41%-- 
IOVAIovance Biotherapeutics1.95-0.02-1.02%-- 
RXRXRecursion Pharmaceuticals5.44-0.08-1.45%-- 
THARTharimmune Inc.3.2+0.25+8.47%0.03PE
Quotes are at least 15-min delayed：2025/11/03 23:25 EST
Industry overview quotes are at least 15 minutes delayed
Business Description
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which haveinitiated a Phase 3 clinical trial for hyperphagia associated with PWS.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.